QSAR study of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide as PARP inhibitors for treatment of cancer

Chemical Biology and Drug Design

Volumn 72, Issue 6, 2008, Pages 575-584

  Riahi, Siavash ^a   Pourbasheer, Eslam ^a   Dinarvand, Rassoul ^b   Ganjali, Mohammad Reza ^a   Norouzi, Parviz ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemometrics; Genetic algorithms; Multiple linear regression; PARP inhibitors; QSAR

Indexed keywords

2 (1 PROPYLPIPERIDIN 4 YL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; AMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; DRUG POTENCY; ENZYME INHIBITION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL MODEL; VALIDATION PROCESS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DATABASES, GENETIC; LEAST-SQUARES ANALYSIS; MODELS, CHEMICAL; NEOPLASMS; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; SOFTWARE;

EID: 56649103442     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00739.x     Document Type: Article

References (53)

1. Tentori L., Portarena I., Graziani G. (2002) Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 45 : 73 85.
2. Griffin R.J., Curtin N.J., Newell D.R., Golding B.T., Durkacz B.W., Calvert A.H. (1995) The role of inhibitors of poly(ADP-ribose) polymerase as resistance modifying agents in cancer therapy. Biochimie 77 : 408 422.
3. Barret J.M., Hill B.T. (1998) DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drug 9 : 105 123.
4. Demurcia G., Demurcia J.M. (1994) Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 19 : 172 176.
5. Satoh M.S., Lindahl T. (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356 : 356 358.
6. Curtin N.J., Golding B.T., Griffin R.J., Newell D.R., Roberts M.J., Srinivasan S. (2000) New PARP inhibitors for chemo- and radio-therapy of cancer. In : deMurcia G., Shall S., editors. From DNA Damage and Stress Signalling to Cell Death: Poly ADP-Ribosylation Reactions. Oxford : Oxford University Press p. 177 206.
7. Molinete M., Vermeulen W., Burkle A., Menissier-de M.J., Kupper J.H., Hoeijmakers J.H. (1993) Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J 12 : 2109 2117.
8. Ding R., Smulson M. (1994) Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influences on genomic stability, chromatin organization, and carcinogen cytotoxicity. Cancer Res 54 : 4627 4634.
9. deMurcia J.M., Niedergang C., Trucco C., Ricoul M., Dutrillaux B., Mark M., Oliver F.J., Masson M., Dierich A., LeMeur M., Walztinger C., Chambon P., deMurcia G. (1997) Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 94 : 7303 7307.
10. Plummer E.R. (2006) Inhibition of poly(ADP-ribose) pollyrnerase in cancer. Curr Opin Pharmacol 6 : 364 368.
11. Horvath E.M., Szabo C. (2007) Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update. Drug News Perspect 20 : 171 181.
12. Ratnam K., Low J.A. (2007) Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 13 : 1383 1388.
13. Donawho C.K., Luo Y., Penning T.D., Bauch J.L., Bouska J.J., Bontcheva-Diaz V.D., Cox B.F. et al. (2007) ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13 : 2728 2737.
14. Lapidus R.G., Tentori L., Graziani G., Leonetti C., Scarsella M., Vergati M., Muzi A., Zhang J. (2005) Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. J Clin Oncol 23 : 225S 225S.
15. Calabrese C.R., Almassy R., Barton S., Batey M.A., Calvert A.H., Canan-Koch S., Durkacz B.W. et al. (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96 : 56 67.
16. Tentori L., Leonetti C., Scarsella M., d'Amati G., Vergati M., Portarena I., Xu W., Kalish V., Zupi G., Zhang J., Graziani G. (2003) Systemic administration of GPI 15427, a novel Poly(ADP-Ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9 : 5370 5379.
17. Li J.-H., Zhang J. (2001) PARP inhibitors. IDrugs 4 : 804 812.
18. Cockcroft X., Dillon K.J., Dixon L., Drzewiecki J., Kerrigan F., Loh V.M., Martin N.M.B., Menear K.A., Smith G.C.M. (2006) Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose) polymerase. Bioorg Med Chem Lett 16 : 1040 1044.
19. Hill D.L. (1972) The Biochemistry and Physiology of Tetrahymena, 1st edn. New York : Academic Press p. 230.
20. Deeb O., Hemmateenejad B. (2007) ANN-QSAR model of drug-binding to human serum albumin. Chem Biol Drug Des 70 : 19 29.
21. Moosavi-Movahedi A.A., Safarian S., Hakimelahi G.H., Ataei G., Ajloo D., Panjehpour S., Riahi S., Mousavi M.F., Mardanyan S., Soltani N., Khalafi-Nezhad A., Sharghi H., Moghadamnia H., Saboury A.A. (2004) QSAR analysis for ADA upon interaction with a series of adenine derivatives as inhibitors. Nucleosides Nucleotides Nucleic Acids 23 : 613 624.
22. Ramirez-Galicia G., Garduno-Juarez R., Hemmateenejad B., Deeb O., Estrada-Soto S. (2007) QSAR study on the relaxant agents from some mexican medicinal plants and synthetic related organic compounds. Chem Biol Drug Des 70 : 143 153.
23. Ramirez-Galicia G., Garduno-Juarez R., Hemmateenejad B., Deeb O., Deciga-Campos M., Moctezuma-Eugenio J.C. (2007) QSAR study on the antinociceptive activity of some morphinans. Chem Biol Drug Des 70 : 53 64.
24. Hemmateenejad B., Miri R., Niroomand U., Foroumadi A., Shafiee A. (2007) A mechanistic QSAR study on the leishmanicidal activity of some 5-substituted-1,3,4-thiadiazole derivatives. Chem Biol Drug Des 69 : 435 443.
25. Liu J., Yang L. (2006) Effect of cholesterol on DMPC phospholipid membranes and QSAR model construction in membrane-interaction QSAR study through molecular dynamics simulation. Bioorg Med Chem 14 : 2225 2234.
26. Verma R.P., Kurup A., Hansch C. (2005) On the role of polarizability in QSAR. Bioorg Med Chem 13 : 237 255.
27. Knaggs M.H., McGuigan C., Harris S.A., Heshmati P., Cahard D., Gilbert I.H., Balzarini J. (2000) A QSAR study investigating the effect of l-alanine ester variation on the anti-HIV activity of some phosphoramidate derivatives of d4T. Bioorg Med Chem Lett 10 : 2075 2078.
28. Toropov A.A., Benfenati E. (2006) QSAR models for Daphnia toxicity of pesticides based on combinations of topological parameters of molecular structures. Bioorg Med Chem 14 : 2779 2788.
29. Khadikar P.V., Phadnis A., Shrivastava A. (2002) QSAR study on toxicity to aqueous organisms using the PI index. Bioorg Med Chem 10 : 1181 1188.
30. Agrawal V.K., Khadikar P.V. (2001) QSAR prediction of toxicity of nitrobenzenes. Bioorg Med Chem 9 : 3035 3040.
31. Zhao W.G., Wang H.G., Li Z.M., Yang Z. (2006) Synthesis and antiviral activity against tobacco mosaic virus and 3D-QSAR of alpha-substituted-1,2,3- thiadiazoleacetamides. Bioorg Med Chem Let 16 : 6107 6111.
32. Pandey V.K., Tusi Z., Tandon M., Joshi M.N., Bajpai S.K. (2003) Synthesis of thiadiazolo-s-triazines for their antiviral activity based on QSAR studies. Indian J Chem B 42 : 2583 2588.
33. Penning T.D., Zhu G.D., Gandhi V.B., Gong J.C., Thomas S., Lubisch W., Grandel R. et al. (2008) Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H- benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem 16 : 6965 6975.
34. Todeschini R., Consonni V. (2000) Handbook of Molecular Descriptors. Weinheim : Wiley-VCH.
35. Kier L.B., Hall L.H. (1986) Molecular Connectivity in Structure-Activity Analysis. Chichetster : RSP-Wiley.
36. Kostantinova E.V. (1996) The discrimination ability of some topological and information distance indices for graphs of unbranched hexagonal systems. J Chem Inf Comp Sci 36 : 54 57.
37. Rucker G., Rucker C. (1993) Counts of all walks as atomic and molecular descriptors. J Chem Inf Comp Sci 33 : 683 695.
38. Galvez J., Garcia R., Salabert M.T., Soler R. (1994) Charge indexes - new topological descriptors. J Chem Inf Comp Sci 34 : 520 525.
39. Broto P., Moreau G., Vandicke C. (1984) Molecular structures: perception, autocorrelation descriptor and sar studies. Eur J Med Chem 19 : 66 70.
40. Caballero J., Fernandez M. (2006) Linear and nonlinear modeling of antifungal activity of some heterocyclic ring derivatives using multiple linear regression and Bayesian-regulated neural networks. J Mol Model 12 : 168 181.
41. Fernandez M., Caballero J. (2006) Bayesian-regularized genetic neural networks applied to the modeling of non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor. J Mol Graph Model 25 : 410 422.
42. Hemmateenejad B., Safarpour M.A., Miri R., Nesari N. (2005) Toward an optimal procedure for PC-ANN model building: prediction of the carcinogenic activity of a large set of drug. J Chem Inf Model 45 : 190 199.
43. Hunger J., Huttner G. (1999) Optimization and analysis of force field parameters by combination of genetic algorithms and neural networks. J Comput Chem 20 : 455 471.
44. Ahmad S., Gromiha M.M. (2003) Design and training of a neural network for predicting the solvent accessibility of proteins. J Comput Chem 24 : 1313 1320.
45. Waller C.L., Bradley M.P. (1999) Development and validation of a novel variable selection technique with application to multidimensional quantitative structure-activity relationship studies. J Chem Inf Comput Sci 39 : 345 355.
46. Aires-de-Sousa J., Hemmer M.C., Casteiger J. (2002) Prediction of H-1 NMR chemical shifts using neural networks. Anal Chem 74 : 80 90.
47. Tute M. 1990) History and objectives of quantitative drug design in advances in drug research. In : Sammes P., Taylor J., editors. Comprehensive Medicinal Chemistry, Vol. 4, Oxford : Pergamon p. 1 32.
48. Hansch C., Taylor J., Sammes P. (1990) Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, Vol. 6. New York : Pergamon p. 1 19.
49. Fernandez M., Tundidor-Camba A., Caballero J. (2005) Modeling of cyclin-dependent kinase inhibition by 1H-pyrazolo[3,4-d] pyrimidine derivatives using artificial neural network ensembles. J Chem Inf Model 45 : 1884 1895.
50. Caballero J., Tundidor-Camba A., Fernandez M. (2007) Modeling of the inhibition constant (Ki) of some cruzain ketone-based inhibitors using 2D spatial autocorrelation vectors and data-diverse ensembles of Bayesian-regularized genetic neural networks. QSAR Comb Sci 26 : 27 40.
51. Pogliani L. (1994) Molecular connectivity descriptors of the physicochemical properties of the alpha-amino-acids. J Phys Chem 98 : 1494 1499.
52. Pogliani L. (2000) From molecular connectivity indices to semiempirical connectivity terms: recent trends in graph theoretical descriptors. Chem Rev 100 : 3827 3858.
53. Baumann K. (2005) Chance correlation in variable subset regression: Influence of the objective function, the selection mechanism, and ensemble averaging. QSAR Comb Sci 24 : 1033 1046.